Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder

References

• World Health Organisation. International classification of diseases, eleventh revision (ICD-11). 2019.
   Google Scholar
• World Health Organisation. Depression and other common mental disorders: global health estimates. 2017.
   Google Scholar
• Office for National Statistics. Cost of living and depression in adults, Great Britain: 29 September to 23 October 2022. 2022.
   Google Scholar
• Department for Health and Social Care. No health without mental health: a cross-government mental health outcomes strategy for people of all ages. 2011.
   Google Scholar
• Strawbridge R, McCrone P, Ulrichsen A, et al. Care pathways for people with major depressive disorder: a European brain council value of treatment study. Eur Psychiatry. 2022;65(1):e36. doi: 10.1192/j.eurpsy.2022.28
   PubMed Web of Science ®Google Scholar
• Mind. We need to talk survey [Internet]. Available from: https://www.mind.org.uk/media-a/4248/we-still-need-to-talk_report.pdf.
   Google Scholar
• Linde K, Sigterman K, Kriston L, et al. Effectiveness of psychological treatments for depressive disorders in primary care: systematic review and meta-analysis. Ann Fam Med. 2015;13(1):56–68. doi: 10.1370/afm.1719
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Depression in adults: treatment and management. 2022.
   Google Scholar
• Public Health England. Prescribed medicines review: summary. 2020.
   Google Scholar
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366. doi: 10.1016/S0140-6736(17)32802-7
   PubMed Web of Science ®Google Scholar
• Nierenberg AA. Residual symptoms in depression: prevalence and impact. J Clin Psychiatry. 2015;76(11):e1480–e1480. doi: 10.4088/JCP.13097TX1C
   PubMedGoogle Scholar
• Treadway MT, Zald DH. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev. 2011;35(3):537–555. doi: 10.1016/j.neubiorev.2010.06.006
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Price J, De Bodinat C, et al. Emotional blunting with antidepressant treatments: a survey among depressed patients. J Affect Disord. 2017;221:31–35. doi: 10.1016/j.jad.2017.05.048
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of depression. [Internet]. 2013 [cited 2023 Nov 29]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression_en.pdf.
   Google Scholar
• Global Market Insights. Antidepressant drugs market size - by drug class (SSRIs, SNRIs, tricyclic antidepressants), by application (Major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder), competitive market share & forecast, 2021 - 2027. 2021.
   Google Scholar
• Sakurai H, Yonezawa K, Tani H, et al. Novel antidepressants in the pipeline (phase II and III): a systematic review of the US clinical trials registry. Pharmacopsychiatry. 2022;55(4):193–202. doi: 10.1055/a-1714-9097
   PubMedGoogle Scholar
• Newswire PR. Antidepressant drugs market global analysis by drugs class, by sales channel, by region, by country: opportunities and forecasts 2018 to 2023: inquire for antidepressant drugs market global research report 2018 with in-depth industry study, analysis and forecasting till 2023. 2018.
   Google Scholar
• Correll CU, Solmi M, Cortese S, et al. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents. World Psychiatry. 2023;22(1):48–74. doi: 10.1002/wps.21056
   PubMed Web of Science ®Google Scholar
• Fava M, Carpenter L, Zajecka J, et al. Proof-of-concept trial of CERC-501 augmentation of antidepressant therapy i n treatment-resistant depression (RAPID KOR). 2016.
   Google Scholar
• Janssen Research & Development, LLC. A study to explore the efficacy of JNJ-67953964 in the treatment of depression. 2023.
   Google Scholar
• Janssen Research & Development, LLC. A study of aticaprant in adult and elderly participants with Major depressive disorder (MDD) (VENTURA-LT). Available from: https://clinicaltrials.gov/study/NCT05518149?term=NCT05518149&rank=1
   Google Scholar
• Janssen Research & Development, LLC. A study of aticaprant as adjunctive therapy in adult participants with Major depressive disorder (MDD) with moderate-to-severe anhedonia and inadequate response to Current antidepressant therapy (VENTURA-1). Available from: https://clinicaltrials.gov/study/NCT05455684?term=NCT05455684&rank=1
   Google Scholar
• Janssen Research & Development, LLC. A study of aticaprant 10 milligrams (mg) as adjunctive therapy in adult participants with MDD with moderate-to-severe anhedonia and inadequate response to Current antidepressant therapy (VENTURA-2). Available from: https://clinicaltrials.gov/study/NCT05550532?term=NCT05550532%20&rank=1
   Google Scholar
• BlackThorn Therapeutics, Inc. Study in Major depressive disorder with BTRX-335140 (NMRA-335140) vs placebo. Available from: https://clinicaltrials.gov/study/NCT04221230?term=NCT04221230&rank=1
   Google Scholar
• Neumora Therapeutics, Inc. Study to evaluate the effects of oral NMRA 335140 versus placebo in participants with Major depressive disorder. Available from: https://clinicaltrials.gov/study/NCT06029426?term=BTRX-335140&rank=5
   Google Scholar
• Neumora Therapeutics, Inc. Study to assess the safety and effectiveness of NMRA-335140-501. Available from: https://clinicaltrials.gov/study/NCT06029439?term=BTRX-335140&rank=3
   Google Scholar
• Alkermes, Inc. ALK33BUP-201: safety and tolerability study of ALKS 33-BUP (ALKS 5461) administration in subjects with MDD. 2011. Available from: https://clinicaltrials.gov/study/NCT01381107?term=ALKS-5461&page=2&rank=17
   Google Scholar
• Alkermes, Inc. A study of ALKS 5461 in healthy volunteers. 2014. Available from: https://clinicaltrials.gov/study/NCT02068105?term=ALKS-5461&rank=6
   Google Scholar
• Alkermes, Inc. A long-term safety study of ALKS 5461. 2014. Available from: https://clinicaltrials.gov/study/NCT02141399?term=ALKS-5461&page=2&rank=14
   Google Scholar
• Alkermes, Inc. A study of different titration schedules of ALKS 5461 in adults with Major depressive disorder (MDD). 2014. Available from: https://clinicaltrials.gov/study/NCT02085135?term=ALKS-5461&page=2&rank=15
   Google Scholar
• Alkermes, Inc. A study to evaluate ALKS 5461 in subjects with Major depressive disorder (MDD). 2011. Available from: https://clinicaltrials.gov/study/NCT01500200?term=NCT01500200&rank=1
   Google Scholar
• Alkermes, Inc. A study of ALKS 5461 for the treatment of Major depressive disorder (MDD) - the FORWARD-3 study. 2014. Available from: https://clinicaltrials.gov/study/NCT02158546?term=ALKS-5461&rank=9
   Google Scholar
• Alkermes, Inc. A study of ALKS 5461 for the treatment of Major depressive disorder (MDD) - the FORWARD-4 study. 2014. Available from: https://clinicaltrials.gov/study/NCT02158533?term=ALKS-5461&rank=7
   Google Scholar
• Alkermes, Inc. A study of ALKS 5461 for the treatment of Major depressive disorder (MDD) - FORWARD-5 study. 2014. Available from: https://clinicaltrials.gov/study/NCT02218008?term=NCT02218008&rank=1
   Google Scholar
• Alkermes, Inc. A study of ALKS 5461 for treatment refractory Major depressive disorder (MDD). 2017. Available from: https://clinicaltrials.gov/study/NCT03188185?term=ALKS-5461&rank=10
   Google Scholar
• Alkermes, Inc. A long term study of ALKS 5461 in the treatment of refractory Major depressive disorder (MDD). 2018. Available from: https://clinicaltrials.gov/study/NCT03610048?term=NCT03610048%20&rank=1
   Google Scholar
• Jelen LA, Stone JM, Young AH, et al. The opioid system in depression. Neurosci Biobehav Rev. 2022;140:104800. doi: 10.1016/j.neubiorev.2022.104800
   PubMed Web of Science ®Google Scholar
• Jelen LA, Young AH, and Mehta MA. Current Topics in Behavioural Neurosciences. 2023. doi: 10.1007/7854_2023_448
   PubMedGoogle Scholar
• Suppes T, Silva R, Cucchiaro J, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2016;173(4):400–407. doi: 10.1176/appi.ajp.2015.15060770
   PubMed Web of Science ®Google Scholar
• Tsai J, Thase ME, Mao Y, et al. Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study. CNS Spectr. 2017;22(2):236–245. doi: 10.1017/S1092852917000074
   PubMed Web of Science ®Google Scholar
• Guo M, Mi J, Jiang Q, et al. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clin Exp Pharmacol Physiol. 2014;41(9):650–656. doi: 10.1111/1440-1681.12265
   PubMed Web of Science ®Google Scholar
• Preskorn S, Macaluso M, Mehra DV, et al. Randomized proof of concept trial of GLYX-13, an N-Methyl-D-Aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract. 2015;21(2):140–149. doi: 10.1097/01.pra.0000462606.17725.93
   PubMed Web of Science ®Google Scholar
• Kamiya M, Sabia HD, Marella J, et al. Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: a randomized, double-blind, placebo-controlled study. J Psychiatr Res. 2020;128:43–51. doi: 10.1016/j.jpsychires.2020.05.017
   PubMed Web of Science ®Google Scholar
• Savitz A, Wajs E, Zhang Y, et al. Efficacy and safety of seltorexant as adjunctive therapy in major depressive disorder: a phase 2b, randomized, placebo-controlled, adaptive dose-finding study. Int J Neuropsychopharmacol. 2021;24(12):965–976. doi: 10.1093/ijnp/pyab050
   PubMed Web of Science ®Google Scholar
• Lalanne L, Ayranci G, Kieffer BL, et al. The kappa opioid receptor: from addiction to depression, and back. Front Psychiatry. 2014/12/30 ed. 2014;5:170. doi: 10.3389/fpsyt.2014.00170
   PubMed Web of Science ®Google Scholar
• Carlezon WJ, Beguin C, DiNieri JA, et al. Depressive-like effects of the κ-opioid receptor agonist salvinorin a on behavior and neurochemistry in rats. J Pharmacol Exp Ther. 2005/10/15 ed. 2006;316(1):440–447. doi: 10.1124/jpet.105.092304
   PubMed Web of Science ®Google Scholar
• Todtenkopf MS, Marcus JF, Portoghese PS, et al. Effects of κ-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacol Berl. 2004/01/17 ed. 2004;172(4):463–470. doi: 10.1007/s00213-003-1680-y
   PubMed Web of Science ®Google Scholar
• Chefer VI, Backman CM, Gigante ED, et al. Kappa opioid receptors on dopaminergic neurons are necessary for kappa-mediated place aversion. Neuropsychopharmacology. 2013/08/08 ed. 2013;38:2623–2631. doi: 10.1038/npp.2013.171
   PubMed Web of Science ®Google Scholar
• Anderson RI, Morales M, Spear LP, et al. Pharmacological activation of kappa opioid receptors: aversive effects in adolescent and adult male rats. Psychopharmacol Berl. 2013/04/23 ed. 2014;231(8):1687–1693. doi: 10.1007/s00213-013-3095-8
   PubMed Web of Science ®Google Scholar
• Cohen BM, Murphy B. The effects of pentazocine, a kappa agonist, in patients with mania. Int J Neuropsychopharmacol [Internet]. 2008 [cited 2023 Oct 17];11(2). Available from: https://academic.oup.com/ijnp/article-lookup/doi/10.1017/S1461145707008073
   Web of Science ®Google Scholar
• Knoll AT, Carlezon WA. Dynorphin, stress, and depression. Brain Res. 2010;1314:56–73. doi: 10.1016/j.brainres.2009.09.074
   PubMed Web of Science ®Google Scholar
• Jacobson ML, Browne CA, Lucki I. Kappa opioid receptor antagonists as potential therapeutics for stress-related disorders. Annu Rev Pharmacol Toxicol. 2020;60(1):615–636. doi: 10.1146/annurev-pharmtox-010919-023317
   PubMedGoogle Scholar
• Peters MF, Zacco A, Gordon J, et al. Identification of short-acting κ-opioid receptor antagonists with anxiolytic-like activity. Eur J Pharmacol. 2011;661(1–3):27–34. doi: 10.1016/j.ejphar.2011.04.017
   PubMed Web of Science ®Google Scholar
• Mague SD, Pliakas AM, Todtenkopf MS, et al. Antidepressant-like effects of κ-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther. 2003/03/22 ed. 2003;305(1):323–330. doi: 10.1124/jpet.102.046433
   PubMed Web of Science ®Google Scholar
• Beardsley PM, Howard JL, Shelton KL, et al. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacol Berl. 2005/09/27 ed. 2005;183(1):118–126. doi: 10.1007/s00213-005-0167-4
   PubMed Web of Science ®Google Scholar
• Grimwood S, Lu Y, Schmidt AW, et al. Pharmacological characterization of 2-methyl-N-((2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors. J Pharmacol Exp Ther. 2011/08/09 ed. 2011;339(2):555–566. doi: 10.1124/jpet.111.185108
   PubMed Web of Science ®Google Scholar
• Rorick-Kehn LM, Witkin JM, Statnick MA, et al. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology. 2014;77:131–144. doi: 10.1016/j.neuropharm.2013.09.021
   PubMed Web of Science ®Google Scholar
• Guerrero M, Urbano M, Kim E-K, et al. Design and synthesis of a novel and selective kappa opioid receptor (KOR) antagonist (BTRX-335140). J Med Chem. 2019;62(4):1761–1780. doi: 10.1021/acs.jmedchem.8b01679
   PubMed Web of Science ®Google Scholar
• Carlezon WA, Krystal AD. Kappa-opioid antagonists for psychiatric disorders: from bench to clinical trials: 2015 ADAA scientific research symposium: KORs in psychiatric illness. Depress Anxiety. 2016;33(10):895–906. doi: 10.1002/da.22500
   PubMed Web of Science ®Google Scholar
• Page S, Mavrikaki MM, Lintz T, et al. Behavioral pharmacology of novel kappa opioid receptor antagonists in rats. Int J Neuropsychopharmacol. 2019:pyz054. doi: 10.1093/ijnp/pyz054
   Web of Science ®Google Scholar
• Margolis EB, Wallace TL, Van Orden LJ, et al. Differential effects of novel kappa opioid receptor antagonists on dopamine neurons using acute brain slice electrophysiology. PLOS ONE. Taylor B, editor. 2020;15(12):e0232864. doi: 10.1371/journal.pone.0232864
   PubMed Web of Science ®Google Scholar
• Jackson KJ, Jackson A, Carroll FI, et al. Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice. Neuropharmacology. 2015;97:270–274. doi: 10.1016/j.neuropharm.2015.05.023
   PubMed Web of Science ®Google Scholar
• Domi E, Barbier E, Augier E, et al. Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders. Neuropsychopharmacology. 2018;43(9):1805–1812. doi: 10.1038/s41386-018-0015-y
   PubMed Web of Science ®Google Scholar
• Zhou Y. Aticaprant (clinically developed kappa-opioid receptor antagonist) combined with naltrexone prevents alcohol “relapse” drinking. J Pharm Pharmacol [Internet]. 2022 [cited 2023 Oct 17];9(1). Available from: https://www.avensonline.org/fulltextarticles/JPP-2327-204X-09-0032.html
   PubMedGoogle Scholar
• Jacobson ML, Wulf HA, Tsuda MC, et al. Sex differences in the modulation of mouse nest building behavior by kappa opioid receptor signaling. Neuropharmacology. 2020;177:108254. doi: 10.1016/j.neuropharm.2020.108254
   PubMed Web of Science ®Google Scholar
• Jacobson ML, Wulf HA, Browne CA, et al. The kappa opioid receptor antagonist aticaprant reverses behavioral effects from unpredictable chronic mild stress in male mice. Psychopharmacol (Berl). 2020;237(12):3715–3728. doi: 10.1007/s00213-020-05649-y
   PubMedGoogle Scholar
• Filliol D, Ghozland S, Chluba J, et al. Mice deficient for δ- and μ-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet. 2000;25(2):195–200. doi: 10.1038/76061
   PubMed Web of Science ®Google Scholar
• Saitoh A, Yamada M. Antidepressant-like effects of δ opioid receptor agonists in animal models. Curr Neuropharmacol. 2012;10(3):231–238. doi: 10.2174/157015912803217314
   PubMed Web of Science ®Google Scholar
• Chen C-M, Ding H, Mabry KM, et al. Enhanced antidepressant-like effects of a delta opioid receptor agonist, SNC80, in rats under inflammatory pain. Pharmacol Biochem Behav. 2022;214:173341. doi: 10.1016/j.pbb.2022.173341
   PubMed Web of Science ®Google Scholar
• Wang J, Song Q, Xu A, et al. Design, synthesis and biological evaluation of aminobenzyloxyarylamide derivatives as selective κ opioid receptor antagonists. Eur J Med Chem. 2017;130:15–25. doi: 10.1016/j.ejmech.2017.02.029
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Study of antidepressant efficacy of a selective, high affinity enkephalinergic agonist in anxious major depressive disorder (AMDD). 2012.
   Google Scholar
• Lee D-S, Law P-Y, Ln W, et al. Differential regulation of mouse and human mu opioid receptor gene depends on the single stranded DNA structure of its promoter and α-complex protein 1. Biomed Rep. 2017;6(5):532–538. doi: 10.3892/br.2017.877
   PubMedGoogle Scholar
• Schattauer SS, Miyatake M, Shankar H, et al. Ligand directed signaling differences between rodent and human κ-opioid receptors. J Biol Chem. 2012;287(50):41595–41607. doi: 10.1074/jbc.M112.381368
   PubMed Web of Science ®Google Scholar
• Rorick-Kehn LM, Witcher JW, Lowe SL, et al. Determining pharmacological selectivity of the kappa opioid receptor antagonist LY2456302 using pupillometry as a translational biomarker in rat and human. Int J Neuropsychopharmacol [Internet]. 2015 cited 2023 Oct 17; 18(2). Available from: https://academic.oup.com/ijnp/article-lookup/doi/10.1093/ijnp/pyu036
   Web of Science ®Google Scholar
• Lowe SL, Wong CJ, Witcher J, et al. Safety, tolerability, and pharmacokinetic evaluation of single‐ and multiple‐ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects. J Clin Pharmacol. 2014;54(9):968–978. doi: 10.1002/jcph.286
   PubMed Web of Science ®Google Scholar
• Reed B, Butelman ER, Fry RS, et al. Repeated administration of opra kappa (LY2456302), a novel, short-acting, selective KOP-r antagonist, in persons with and without cocaine dependence. Neuropsychopharmacol. 2018;43(4):739–750. doi: 10.1038/npp.2017.205
   PubMed Web of Science ®Google Scholar
• Krystal AD, Pizzagalli DA, Smoski M, et al. A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia. Nat Med. 2020;26(5):760–768. doi: 10.1038/s41591-020-0806-7
   PubMed Web of Science ®Google Scholar
• Fava M, Mazzone E, Freeman M, et al. Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression. Ann Clin Psychiatry [Internet]. 2020 [cited 2023 Oct 17];33(1). Available from: https://www.aacp.com/article/abstract/double-blind-placebo-controlled-proof-of-concept-trial-of-a-kappa-selective-opioid-receptor-antagonist-augmentation-in-treatment-resistant-depression/
   Web of Science ®Google Scholar
• Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004;65(7):959–965. doi: 10.4088/JCP.v65n0712
   PubMed Web of Science ®Google Scholar
• Opioid antagonists. Meylers side eff drugs int encycl adverse drug react interact [internet]. Elsevier; 2006 [cited 2023 Oct 17]. p. 2639. Available from: https://linkinghub.elsevier.com/retrieve/pii/B0444510052001972
   Google Scholar
• Urbano M, Guerrero M, Rosen H, et al. Antagonists of the kappa opioid receptor. Bioorg Med Chem Lett. 2014;24(9):2021–2032. doi: 10.1016/j.bmcl.2014.03.040
   PubMed Web of Science ®Google Scholar
• Stanciu CN, Glass OM, Penders TM. Use of buprenorphine in treatment of refractory depression—A review of current literature. Asian J Psychiatr. 2017;26:94–98. doi: 10.1016/j.ajp.2017.01.015
   PubMed Web of Science ®Google Scholar
• Ragguett R-M, Rong C, Rosenblat JD, et al. Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder. Expert Opin Drug Metab Toxicol. 2018;14(4):475–482. doi: 10.1080/17425255.2018.1459564
   PubMed Web of Science ®Google Scholar